Patheon halts Omnicef manufacturing
Executive Summary
Patheon subsidiary CEPH voluntarily suspends production of Abbott's Omnicef (cefdinir) powder for oral suspension at its Puerto Rico manufacturing facility after receiving a warning letter from FDA, company says Sept. 28. The CEPH facility was cited by FDA for "out of specification results" due to fill weight variations, failure to implement corrective actions to assure unit product quality, and failure to act on post-marketing adverse event reports that "stated lack of effectiveness." Abbott and Patheon have sent teams to the facility to ensure that corrective measures are implemented. Patheon is Abbott's only Omnicef supplier, but Abbott says it will be able to supply the oral suspension antibiotic to patients requiring it. Production of Omnicef 300 mg capsules remains unaffected...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.